Jérémie Calais, MD, PhD
Jérémie Calais, MD, PhD, is director of the theranostics and clinical research programs, Ahmanson Translational Theranostics Division, and associate professor, Department of Molecular and Medical Pharmacology, at the University of California, Los Angeles. He leads a clinical research program of nuclear medicine and theranostics combining radionuclide imaging and therapy.
Articles by Jérémie Calais, MD, PhD
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
The panel continues discussing their phase 3 PSMA PET/CT trial expectations for the final data readout in 2025.
The panel from UCLA highlights their study on the impact of PSMA PET/CT on prostate cancer salvage radiotherapy management.
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
The first annual PSMA Conference focused on updates in the field of PSMA-based treatments.
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Drs. Calais, Wallis discuss a post-hoc that showed PSMA PET as effective for treating pelvic, extrapelvic recurrent PC.
Drs. Czernin and Calais explain how supply has become a large issue for Lutetium-177–PSMA-617 and strategies to overcome ...
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.